Seifi Razieh, Ayat Hoda, Ahadi Ali Mohammad
Department of Genetics, Shahrekord University, Rahbar Blvd, P.O Box 115 Shahrekord, Iran.
Mol Biol Res Commun. 2023;12(1):27-36. doi: 10.22099/mbrc.2023.46450.1804.
Scorpion venom contains various toxin peptides with pharmacological and biological properties. Scorpion toxins specifically interact with membrane ion channels which play key roles in progression of cancer. Therefore, scorpion toxins have received special attention for targeting cancer cells. Two new toxins MeICT and IMe-AGAP, isolated from Iranian yellow scorpion, interact specifically with chloride and sodium channels, respectively. Anti-cancer properties of MeICT and IMe-AGAP have been determined before, in addition they show 81 and 93% similarity with two well-known anti-cancer toxins, CTX and AGAP, respectively. The aim of this study was construction of a fusion peptide MeICT/IMe-AGAP to target different ion channels involved in cancer progression. Design and structure of the fusion peptide were investigated by bioinformatics studies. Two fragments encoding MeICT and IMe-AGAP were fused using overlapping primers by SOEing-PCR. MeICT/IMe-AGAP chimeric fragment was cloned into pET32Rh vector, expressed in host and analyzed by SDS-PAGE. The studies showed that chimeric peptide with GPSPG linker preserved the three-dimensional structure of both peptides and can be functional. Due to the high expression of chloride and sodium channels in various cancer cells, MeICT/IMe-AGAP fusion peptide can be used as an effective agent to target both channels in cancers, simultaneously.
蝎毒含有多种具有药理和生物学特性的毒素肽。蝎毒素与膜离子通道特异性相互作用,而膜离子通道在癌症进展中起关键作用。因此,蝎毒素在靶向癌细胞方面受到了特别关注。从伊朗黄蝎中分离出的两种新毒素MeICT和IMe - AGAP,分别与氯离子通道和钠离子通道特异性相互作用。此前已确定了MeICT和IMe - AGAP的抗癌特性,此外,它们分别与两种著名的抗癌毒素CTX和AGAP具有81%和93%的相似性。本研究的目的是构建一种融合肽MeICT/IMe - AGAP,以靶向参与癌症进展的不同离子通道。通过生物信息学研究对融合肽的设计和结构进行了研究。使用重叠引物通过SOEing - PCR将编码MeICT和IMe - AGAP的两个片段融合。将MeICT/IMe - AGAP嵌合片段克隆到pET32Rh载体中,在宿主中表达并通过SDS - PAGE进行分析。研究表明,带有GPSPG接头的嵌合肽保留了两种肽的三维结构并且具有功能活性。由于氯离子通道和钠离子通道在各种癌细胞中高表达,MeICT/IMe - AGAP融合肽可作为一种有效试剂同时靶向癌症中的这两种通道。